Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633818 | 0.82 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL28076845 | 0.81 | — | — | |
| SCHEMBL210521 | 0.79 | — | — | |
| SCHEMBL28304083 | 0.79 | — | — | |
| SCHEMBL28641663 | 0.79 | — | — | |
| SCHEMBL25539958 | 0.79 | CYP19A1 (0.36) | CYP19A1CYP11B1CYP11B2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL3124271 | 0.77 | — | — | |
| Water SCHEMBL28716806 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL9230735 | 0.77 | CYP19A1 (0.41) | CYP19A1NFKB1QPCTHSD17B10QPCTL | |
| Bromide SCHEMBL28863695 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239768-A1 | METHOD FOR PREPARING XANTHINE OXIDASE INHIBITOR | LG CHEM, LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11572355-B2 | Methods for synthesizing vinylidenes and alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572355-B2 | Methods for synthesizing vinylidenes and alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220017494-A1 | METHODS FOR SYNTHESIZING VINYLIDENES AND ALKENES | UNITED STATES DEPARTMENT OF ENERGY | 2022-01-20 | — | — | US | disclosed |
| WO-2021126728-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10851209-B2 | Amphiphilic macromolecules, contact lens thereof and preparing methods thereof | NATIONAL CHIAO TUNG UNIVERSITY (TW) | 2020-12-01 | — | — | US | disclosed |
| WO-2020136170-A2 | NUCLEOSIDES AND NUCLEOTIDES WITH 3'-HYDROXY BLOCKING GROUPS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020128525-A1 | NRTI THERAPIES | THE UNIVERSITY OF LIVERPOOL (GB) | 2020-06-25 | — | — | WO | disclosed |
| US-10626091-B2 | Process for the preparation of enzalutamide | LAURUS LABS LIMITED (IN) | 2020-04-21 | — | — | US | disclosed |
| EP-2098524-A1 | Process for preparing enantiomerically pure indolopyrinidines | 4SC AG (DE) | 2009-09-09 | — | — | EP | disclosed |
| US-7491739-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| WO-2008137779-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008101728-A1 | METHOD FOR PRODUCING AZONIASPIRONORTROPINE ESTERS AND NORTROPAN-3-ONE COMPOUNDS | K.H.S. PHARMA HOLDING GMBH (DE) | 2008-08-28 | — | — | WO | disclosed |
| US-20080182881-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| WO-2008083491-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2008-07-17 | — | — | WO | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7345064-B2 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2004087646-A2 | PYRROLIDINO-1,2-DICARBOXY-1-(PHENYLAMIDE)-2-(4-(3-OXO-MORPHOLINO-4-YL)-PHENYLAMIDE) DERIVATIVES AND RELATED COMPOUNDS FOR USE AS INHIBITORS OF COAGULATION FACTOR XA IN THE TREATMENT OF THROMBO-EMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182881-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | CYP19A1 1018/4885NFKB1 66/4885QPCT 3130/4885 |
| US-11572355-B2 | Methods for synthesizing vinylidenes and alkenes | ALKBH2, VAV1, ALKBH3 | CYP19A1 526/4885NFKB1 3393/4885QPCT 872/4885 |
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | CYP19A1 591/4885NFKB1 742/4885QPCT 3790/4885 |
| US-10626091-B2 | Process for the preparation of enzalutamide | KLK4, KLK5, KLK1 | CYP19A1 17/4885NFKB1 1781/4885QPCT 268/4885 |
| US-20240239768-A1 | METHOD FOR PREPARING XANTHINE OXIDASE INHIBITOR | XDH, AOX1, PNPO | CYP19A1 242/4885NFKB1 2333/4885QPCT 1130/4885 |
| US-20220017494-A1 | METHODS FOR SYNTHESIZING VINYLIDENES AND ALKENES | ALKBH2, VAV1, ALKBH3 | CYP19A1 526/4885NFKB1 3393/4885QPCT 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.